Overview
Methotrexate (MTX) is a medication used in various therapeutic settings. Neurotoxicity is a potential adverse effect associated with MTX treatment, particularly with high-dose regimens.
Diagnosis
No specific diagnostic criteria or grading scales for MTX neurotoxicity are mentioned in the provided abstracts.Management
No specific management strategies for MTX neurotoxicity are detailed in the provided abstracts.Special Populations
Pediatrics: Methotrexate pharmacokinetics differ significantly between neonates, children, and adults, with neonates having a higher volume of distribution and higher apparent clearance compared to children and adults 1.
Renal Function: Renal function significantly influences MTX clearance 1.
Genetic Factors: Mutations in certain genes can reduce MTX clearance by 8-35.3% or increase it by 15-48% 1.
Body Size: Bodyweight and body surface area (BSA) significantly influence MTX apparent clearance and volume of distribution 1.Key Recommendations
Individualized dose adjustment of methotrexate is necessary due to factors influencing its pharmacokinetics 1. (Evidence: Moderate)
Consider the impact of renal function on methotrexate clearance when determining dosage 1. (Evidence: Moderate)
Be aware that genetic variations can alter methotrexate clearance 1. (Evidence: Moderate)References
1 Yang Y, Liu Z, Chen J, Wang X, Jiao Z, Wang Z. Factors influencing methotrexate pharmacokinetics highlight the need for individualized dose adjustment: a systematic review. European journal of clinical pharmacology 2024. link
2 Vazirian F, Samadi S, Rahimi H, Sadeghi M, Mohammadpour AH. Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review. Cancer chemotherapy and pharmacology 2022. link